Conversely, CUMS increased GluN2B expression, a finding that aligns with the studies reporting that antagonism of GluN2B‐containing NMDA receptors induces antidepressant effects causing significant behavioral changes in both clinical patients and rodent models of depression [36–40]. Here, GRIN2B is linked to major depressive disorder.